symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
IOBT,1.1,0,142410,77432630,0,1.05-3.52,-0.01,"IO Biotech, Inc.",USD,0001865494,US4497781090,449778109,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.iobiotech.com,"IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.",Dr. Mai-Britt  Zocca Ph.D.,Healthcare,DK,57,45 70 70 29 80,Ole Maal√∏es Vej 3,Copenhagen,,2200,,0,https://financialmodelingprep.com/image-stock/IOBT.png,2021-11-05,False,False,True,False,False
